Bristol-Myers Squibb (BMY) Approaches New Upside Target of $33.83 Financial News Network Online The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. In the past 52 weeks, shares of Bristol-Myers Squibb have traded ... |
